javier pinilla-ibarz, md, phd: phase iii data to support usage of bruton's tkis
Published 8 years ago • 22 plays • Length 0:31
Download video MP4
Download video MP3
Similar videos
-
0:59
javier pinilla-ibarz, md, phd: use of bruton's tyrosine kinase inhibitor
-
0:45
javier pinilla-ibarz, md, phd: options to prolong survival
-
0:59
javier pinilla-ibarz, md, phd: principle treatment options for patients with a 17p deletion
-
0:47
javier pinilla-ibarz, md, phd: dose intensity
-
26:38
🇩🇪 we are one, with petra elmendorff, in german - live on july, 24th, 2020
-
1:23:26
why are we muslims and not christians? - dr. laurence brown
-
18:51
signs & symptoms of stroke and the blood vessels of the brain
-
1:04
javier pinilla-ibarz, md, phd: additional chemo-immunotherapy
-
0:54
javier pinilla-ibarz, md, phd: significance of treat to progression
-
1:12
javier pinilla-ibarz, md, phd: treatment options for patients with previously treated cll
-
1:08
javier pinilla-ibarz, md, phd - malignant hematology
-
0:47
javier pinilla-ibarz, md, phd: relapse following purine analog therapy
-
0:42
javier pinilla-ibarz, md, phd: bendamustine/rituximab therapy
-
1:48
dr. pinilla-ibarz on the role of chemotherapy in cll
-
0:52
dr. pinilla-ibarz discusses advancements in cml
-
0:55
dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
-
5:06
treatment-free remission in cml
-
1:14
dr. pinilla-ibarz on the impact of venetoclax in cll
-
1:24
how ibrutinib has transformed the treatment paradigm of cll
-
6:55
emerging therapies for cml
-
2:55
paul barr, md: use of bruton's tyrosine kinase inhibitor
-
4:11
rationale for novel combinations in cll
Clip.africa.com - Privacy-policy